Products

As of April 2022

Brand Name Launch Indications Licensor
1 NOBELZIN® Apr-08 Wilson’s disease Teva
2 LUNABELL® LD Jul-08 dysmenorrhea Janssen
3 NOBELBAR® Dec-08 neonatal seizures,
status epilepticus
In-house/
Kagawa Univ
4 Fostoin® Jan-12 status epilepticus,
prevention of postoperative seizures, etc.
In-house
5 GLIADEL® Jan-13 malignant glioma Eisai
6 INDACIN® Jan-13 patent ductus arteriosus of prematurity Lundbeck
7 COSMEGEN® Jan-13 Wilms’ tumor,
chorionepitelioma,
pediatric solid malignant tumor, etc.
Lundbeck
8 LUNABELL® ULD Sep-13 dysmenorrhea Janssen
9 Alabel® Sep-13 diagnosis of malignant glioma medac
10 Unitalc® Dec-13 prevention of recurrent malignant pleural effusion Novatech/
Nagoya Medical Center
11 Respia® Dec-14 apnea of prematurity Nippon Boehringer
(co-development)
12 RAPALIMUS® Dec-14 lymphangioleiomyomatosis Pfizer/
Niigata Univ
13 ZANOSAR® Feb-15 gastroenteropancreatic neuroendocrine tumor Keocyt
14 NOBELZIN® Mar-17 hypozincemia In-house
15 RAPALIMUS® Gel Jun-18 tuberous sclerosis-associated skin lesions Osaka Univ/
In-house
16 TITANBRIDGE®
(medical device)
Jul-18 adductor spasmodic dysphonia TRI
(Translational Research Center
for Medical Innovation)/
Kumamoto Univ
17 JEMINA® Oct-18 dysmenorrhea In-house
18 RETYMPA® Dec-19 tympanic perforation TRI/
Kaken
19 Melatobel® Jun-20 Sleep-onset difficulty associated with neurodevelopmental disorder in children In-house
20 RAPALIMUS® Sep-21 refractory lymphatic disease [lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham's disease, lymphangiectasia] Gifu Univ
21 Unitalc® Mar-22 Inoperable Secondary Intractable Pneumothorax Nagoya Medical Center
22 LUNABELL®LD/ULD Mar-22 Coordinating the Timing of Initiation of Modulated Ovarian Stimulation in Assisted Reproductive Technology. -
23 JEMINA® Mar-22 Coordinating the Timing of Initiation of Modulated Ovarian Stimulation in Assisted Reproductive Technology. -
Research and Development

R&D of Nobelpharma

Pipeline

Products

PAGE TOP
  1. HOME
  2. Research and Development
  3. Products